Device Trial Radar · NCT03641677
Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Apr 21, 2019
Primary completion
Dec 18, 2023
Study completion Jan 18, 2024
Sponsor
- Lead sponsor
- Lung Bioengineering Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 22, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and effectiveness of the Centralized Lung Evaluation System (CLES) in enabling evaluation of potential donor lungs not otherwise used for transplant into subjects with end stage, survival-limiting lung disease in need of lung transplantation. This will be accomplished by evaluating subject survival at the later of 12 months or hospital discharge post-transplant.
Conditions
- Lung Diseases
Interventions
Centralized Lung Evaluation SystemDevice
Assessment of allograft lung for transplant suitability
Lung TransplantProcedure
Orthotopic single or double lung transplantation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12 Month Survival or Freedom From MortalityTime frame: 12 Months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Florida
Jacksonville, Florida
Emory University Hospital
Atlanta, Georgia
University of Maryland Medical System
Baltimore, Maryland
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.